Week In Review: Zhaoke Signs $130 Million Deal For Vision-Improving Eyedrops
May 14, 2022 at 14:30 PM EDT
Zhaoke Ophthalmology acquired China/Southeast Asia rights for two eyedrop candidates from Visus Therapeutics in a $130 million deal. Meanwhile, Coherus Biosciences returned the US rights to market an Innovent Avastin biosimilar.
